Caribou Biosciences shares ticked up by 0.6% on Tuesday, with trading volume rising to 1,035,077 shares, representing a 13% increase over its 918,003-share daily average. The heightened activity underscores renewed investor interest following recent corporate milestones and market commentary.

Over the past month, three major brokerages have raised their target valuations on Caribou Biosciences. Citigroup lifted its target from $5.00 to $8.00 while maintaining a Buy recommendation. HC Wainwright boosted its view from $3.00 to $9.00, also endorsing a Buy. Truist Financial set its target at $7.00 with a positive outlook. One firm continues to hold a Sell stance, resulting in a consensus Hold rating and an average target of $8.00 across all coverage.

In its latest quarter, Caribou Biosciences reported revenue of $2.20 million, topping consensus by 13%. R&D-heavy operations produced an EPS loss of $0.30, better than the expected $0.36 shortfall. The company’s negative net margin reached 1,690%, while return on equity stood at –69.9%. Analysts project a full-year EPS loss of $1.64 driven by ongoing clinical and platform investments.

Institutional ownership accounts for 77.5% of Caribou’s outstanding shares. Vanguard Group increased its stake by 3.4% in Q3, adding 137,060 shares. Millennium Management more than doubled its position, acquiring 1.67 million additional shares. Aberdeen Group boosted holdings by 54.7%, and Bank of America grew its stake by 32.8%. AQR Capital Management expanded its position by 742% in Q1, reflecting growing confidence among hedge funds.